{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:43Z","timestamp":1791302503266,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaccas.2026.108897","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:38:06Z","timestamp":1781782686000},"page":"108897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Pericarditis After Targeted Kinase Inhibitor Therapy in Acute Leukemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Marina P\u00e9rez","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rosa","family":"Carranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2026.108897_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2026.108897_bib2","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccas.2026.108897_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jaccas.2026.108897_bib4","article-title":"Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature","volume":"9","author":"Kalkan","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.jaccas.2026.108897_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/circ.142.suppl_3.12978","article-title":"Abstract 12978: identification of cardiovascular adverse effects associated with midostaurin\u2014A WHO Pharmacovigilance Database analysis","volume":"142","author":"Choudhary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccas.2026.108897_bib6","article-title":"Heartbreak from gilteritinib: two case reports of delayed onset cardiotoxicity","volume":"2025","author":"Dutta","year":"2025","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.jaccas.2026.108897_bib7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2026.108897_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926020565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926020565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:37:55Z","timestamp":1791301075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926020565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":8,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666084926020565"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108897","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Pericarditis After Targeted Kinase Inhibitor Therapy in Acute Leukemia","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"108897"}}